Hiroto Hatakeyama

ResearcherID Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

Pharmaceutics

Journal for immunotherapy of cancer

Journal of clinical medicine

Cancers

Chiba University

Hokkaido University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Chiba University Oct 01 2019

Japan

Associate Professor :: Graduate School of Pharmaceutical Sciences

Chiba University Jan 12 2016 - Sep 30 2019

Japan

Assistant Professor :: Graduate School of Pharmaceutical Sciences

University of Texas MD Anderson Cancer Center Oct 01 2013 - Jan 05 2016

United States

Postdoctoral fellow :: Department of Gynecologic Oncology

Japan Society for the Promotion of Science Oct 01 2013 - Sep 30 2015

Japan

JSPS Overseas Research Fellow

Hokkaido University Apr 01 2009 - Sep 30 2013

Japan

Project Assistant Professor :: Graduate School of Pharmaceutical Sciences

Hokkaido University Apr 01 2008 - Mar 31 2009

Japan

Assistant Professor :: Graduate School of Pharmaceutical Sciences

Education History

Hokkaido University Apr 01 2005 - Mar 25 2008

Japan

PHD :: Graduate School of Pharmaceutical Sciences

Publications

Jessica Anindita, Hiroki Tanaka, Takuma Yamakawa, Yuka Sato, Chika Matsumoto, Kota Ishizaki, Taiji Oyama, Satoko Suzuki, Keisuke Ueda, Kenjirou Higashi, Kunikazu Moribe, Kasumi Sasaki, Yumika Ogura, Etsuo Yonemochi, Yu Sakurai, Hiroto Hatakeyama, Hidetaka Akita
The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles. Pharmaceutics 16 (2) (2024)
Jessica Anindita, Hiroki Tanaka, Takuma Yamakawa, Yuka Sato, Chika Matsumoto, Kota Ishizaki, Taiji Oyama, Satoko Suzuki, Keisuke Ueda, Kenjirou Higashi, Kunikazu Moribe, Kasumi Sasaki, Yumika Ogura, Etsuo Yonemochi, Yu Sakurai, Hiroto Hatakeyama, Hidetaka Akita
The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles. Pharmaceutics 16 (2) (2024)
Jessica Anindita, Hiroki Tanaka, Ryotaro Oyama, Shinya Hagiwara, Daiki Shirane, Sakura Taneichi, Yuta Nakai, Kota Tange, Hiroto Hatakeyama, Yu Sakurai, Hidetaka Akita
Development of a Ready-to-Use-Type RNA Vaccine Carrier Based on an Intracellular Environment-Responsive Lipid-like Material with Immune-Activating Vitamin E Scaffolds. Pharmaceutics 15 (12) (2023)
Jessica Anindita, Hiroki Tanaka, Ryotaro Oyama, Shinya Hagiwara, Daiki Shirane, Sakura Taneichi, Yuta Nakai, Kota Tange, Hiroto Hatakeyama, Yu Sakurai, Hidetaka Akita
Development of a Ready-to-Use-Type RNA Vaccine Carrier Based on an Intracellular Environment-Responsive Lipid-like Material with Immune-Activating Vitamin E Scaffolds. Pharmaceutics 15 (12) (2023)
Takahiro Arai, Tomomi Kokubo, Ruiheng Tang, Hirohito Abo, Ayu Terui, Jotaro Hirakawa, Hidetaka Akita, Hiroto Kawashima, Akihiro Hisaka, Hiroto Hatakeyama
Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor. Journal for immunotherapy of cancer 10 (12) (2022)
Nako Maishi, Yu Sakurai, Hiroto Hatakeyama, Yui Umeyama, Takashi Nakamura, Rikito Endo, Mohammad Towfik Alam, Cong Li, Dorcas Akuba-Muhyia Annan, Hiroshi Kikuchi, Hirofumi Morimoto, Masahiro Morimoto, Kosuke Akiyama, Noritaka Ohga, Yasuhiro Hida, Hideyoshi Harashima, Kyoko Hida
Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system. Cancer science 113 (5) (2022)
Takahiro Arai, Tomomi Kokubo, Ruiheng Tang, Hirohito Abo, Ayu Terui, Jotaro Hirakawa, Hidetaka Akita, Hiroto Kawashima, Akihiro Hisaka, Hiroto Hatakeyama
Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor. Journal for immunotherapy of cancer 10 (12) (2022)
Takahiro Arai, Tomomi Kokubo, Ruiheng Tang, Hirohito Abo, Ayu Terui, Jotaro Hirakawa, Hidetaka Akita, Hiroto Kawashima, Akihiro Hisaka, Hiroto Hatakeyama
Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor. Journal for immunotherapy of cancer 10 (12) (2022)
Toya Okawa, Kurumi Hara, Momoko Goto, Moe Kikuchi, Masataka Kogane, Hiroto Hatakeyama, Hiroki Tanaka, Daiki Shirane, Hidetaka Akita, Akihiro Hisaka, Hiromi Sato
Effects on Metabolism in Astrocytes Caused by cGAMP, Which Imitates the Initial Stage of Brain Metastasis. International journal of molecular sciences 22 (16) (2021)
Taiki Kurino, Reiko Matsuda, Ayu Terui, Hiroyuki Suzuki, Tomomi Kokubo, Tomoya Uehara, Yasushi Arano, Akihiro Hisaka, Hiroto Hatakeyama
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. Journal for immunotherapy of cancer 8 (1) (2021)
Riki Cho, Yu Sakurai, Haleigh Sakura Jones, Hidetaka Akita, Akihiro Hisaka, Hiroto Hatakeyama
Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers 12 (12) (2020)
Akihiro Hisaka, Hideki Yoshioka, Hiroto Hatakeyama, Hiromi Sato, Yoshihiro Onouchi, Naohiko Anzai
Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World. Journal of clinical medicine 9 (6) (2020)

Hiroto Hatakeyama.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiroto Hatakeyama